Influenza Human clinical trials

Explore recruiting influenza human clinical trials.

Recruiting influenza human studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Influenza Human trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An open label, single arm study to evaluate single and multiple dose pharmacokinetics, safety and tolerability, and to explore clinical outcomes of treatment with intravenous (IV) zanamivir in neonates and infants under 6 months of age with confirmed complicated influenza infection.

Spain, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2a randomized, observer-blind, study to evaluate the immunogenicity and safety of mRNA-based multivalent seasonal influenza vaccine candidates in adults 18 years of age and older.

Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2a randomized, observer-blind, study to evaluate the immunogenicity and safety of mRNA-based multivalent seasonal influenza vaccine candidates in adults 18 years of age and older

Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

Influenza Human trials by city

Influenza Human in Toronto Influenza Human in Vancouver Influenza Human in Montreal Influenza Human in Calgary Influenza Human in Edmonton Influenza Human in Ottawa Influenza Human in Winnipeg Influenza Human in Quebec City Influenza Human in Hamilton Influenza Human in Kitchener Influenza Human in London Influenza Human in Halifax Influenza Human in New York Influenza Human in Los Angeles Influenza Human in Chicago Influenza Human in Houston

Influenza Human clinical trials

Recruiting influenza human studies right now

Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults

Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against Influenza

Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)

Study of the Safety, Tolerability, and Pharmacokinetic Profile of Ascending Doses of Ingavirin Forte, Capsules, Folliwing Single and Subsequent Multiple Oral Administration in Healthy Volunteers

A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults

Study to Evaluate the Efficacy, Safety, and Tolerability of the Ingavirin Forte Capsules (Valenta Pharm JSC) at Different Doses in Subjects With Influenza and Other Acute Respiratory Viral Infections.

Study Evaluating the Impact of Using Triplex Rapid Diagnostic Tests (SARS-CoV-2/Influenza/RSV) on Antibiotic Prescribing

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Clinical Trials of Quadrivalent Influenza Vaccine

Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection

Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women

A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza

Also recruiting in Europe

An open label, single arm study to evaluate single and multiple dose pharmacokinetics, safety and tolerability, and to explore clinical outcomes of treatment with intravenous (IV) zanamivir in neonates and infants under 6 months of age with confirmed complicated influenza infection.

A Phase 2a randomized, observer-blind, study to evaluate the immunogenicity and safety of mRNA-based multivalent seasonal influenza vaccine candidates in adults 18 years of age and older.

A Phase 2a randomized, observer-blind, study to evaluate the immunogenicity and safety of mRNA-based multivalent seasonal influenza vaccine candidates in adults 18 years of age and older

Influenza Human trials by city

Other conditions